China
Africa
Explore chapters and articles related to this topic
Breast Cancer
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Amy Case, Gwenllian Edwards, Catherine Pembroke
Bone is the most common site of metastases, and approximately 70% of patients dying from metastatic breast cancer have evidence of bone metastases at post-mortem analysis.187 Skeletal complications from bony metastases also referred to as skeletal-related events (SREs) are responsible for major morbidity and include hypercalcemia, pathologic fracture, spinal cord compression (Figure 6.9), and the need for radiotherapy treatment or surgery to bone. Bone metastases are the common cause of cancer-related pain affecting the patient’s quality of life, but bone pain is not included in the definition of SREs and is instead measured as a separate outcome in clinical trials. Management options for bone metastases include systemic therapies (chemotherapy, endocrine therapy, and targeted therapies), local therapies (radiotherapy and surgery), and bone-targeting agents (osteoclast inhibition) that reduce SREs such as denosumab and bisphosphonates.
Bone metastases
Published in Anju Sahdev, Sarah J. Vinnicombe, Husband & Reznek's Imaging in Oncology, 2020
Rupert Berkeley, Muaaze Ahmad, Rikin Hargunani
A wide variety of primary malignancies can disseminate to bones, but those that most commonly result in bone metastases arise from breast, prostate, lung, thyroid, and kidney. Breast and prostate carcinoma are responsible for the majority of skeletal metastases found in women and men, respectively (4).
Applications of Radioisotopes in the Diagnosis and Treatment of Thyroid Disorders
Published in Madan Laxman Kapre, Thyroid Surgery, 2020
Chandrasekhar Bal, Meghana Prabhu, Dhritiman Chakraborty, K. Sreenivasa Reddy, Saurabh Arora
RAI therapy of iodine-avid bone metastases has been associated with improved survival and should be employed, although RAI is rarely curative. The RAI activity administered can be given empirically (100–200 mCi) or determined by dosimetry. Patients undergoing RAI therapy for bone metastases should also be considered for directed therapy of bone metastases that are visible on anatomical imaging. Bone metastases may include surgery, external beam radiation therapy, and other local treatment modalities [11] (Figure 21.6).
The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission
Published in Annals of Medicine, 2023
Bo Huang, Fang-Cai Wu, Wei-Dong Wang, Bu-Qing Shao, Xiao-Mei Wang, Ying-Miao Lin, Guo-Xing Zheng, Ming-Ming Dong, Can-Tong Liu, Yi-Wei Xu, Xin-Jia Wang
Currently, the prognostic predictors of bone metastasis include the features of original tumor, tumor markers, expression of selected genes, and related clinical manifestations [6–8]. Are there any more convenient examination indicators that can make clinicians to preliminarily judge the prognosis of BC bone metastasis for patients at the early stage of hospitalization? Nowadays, in order to predict the outcome and guide the clinical management, more and more researchers prefer to establish clinical prognosis models [9,10]. As a popular quantitative predictive tool, nomogram was usually used to predict the prognosis of cancer patients [7,11,12]. Recently, Mao et al. [13] have constructed a nomogram in combination with peripheral blood signatures and selected clinical characteristics, which predicted the prognosis of individual patients with nasopharyngeal carcinoma.
A case of cranial bone metastasis after fertility-sparing approach in endometrial cancer
Published in Journal of Obstetrics and Gynaecology, 2022
Özer Birge, Mehmet Sait Bakır, Saliha Sağnıç, Can Dinc, Hasan Aykut Tuncer, Tayup Simsek
Under 60 years of age, bone metastasis was observed as 117 (0.4%) (Yang et al. 2019). In a literature review 3 cases with femoral metastasis and 2 cases with metastasis to the skull bones were reported (Makris et al. 2018). The ages of the patients with femoral metastasis were 59,48 and 58, and bone metastasis of two cases was detected at the time of endometrial cancer diagnosis. The ages of two cases with skull metastasis were 45 and 72, and the interval between first diagnosis and the skull bone metastasis were 36 and 24 months. Bone metastasis was detected 24 months after diagnosis in our patient. In the same review, Makris stated that there were only two patients with bone metastasis in their 30 s in the literature, one with pubic bone metastasis at the age of 32 and the other at the age of 39 with ischial bone metastasis. Most of the patients with bone metastasis presented with pain. Our patient also presented with hip pain and difficulty in walking.
Assessing the Protective Effect of Moringa oleifera Extract against Bone Metastasis: An In Vitro Simulated Digestion Approach
Published in Nutrition and Cancer, 2022
Kinjal P. Bhadresha, Nayan K. Jain, Rakesh M. Rawal
Bone metastasis is a common hurdle of progressive cancer, and once cancer has spread to the bones it can rarely be treated, but often it can still be cured to slow its growth (1, 2). Recent treatments that have been approved for the therapies of bone metastasis delay the occurrence of skeletal-related events and can extend the patient’s lifespan by a few years (3). However, they will not cure or cause the deterioration of recognized bone metastasis, and different side effects are developed after extended treatment. Hence, novel treatments are rigorously required. For many years plants and their bioactive compounds have been used as the primary source of medical treatment. Thus, research has developed into studying the potential properties of plants and has attracted the attention of researchers worldwide. There are convincing suggestions from in vitro and in vivo preclinical studies that support the use of compounds derived from plants to treat numerous forms of cancers counting bone metastasis (4).